Plus Therapeutics, Inc.
PSTV
$0.59
-$0.03-4.84%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 31.26% | -25.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 31.26% | -25.00% | |||
| Cost of Revenue | -29.04% | -19.67% | |||
| Gross Profit | 120.66% | 9.95% | |||
| SG&A Expenses | -40.75% | -9.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.28% | -13.50% | |||
| Operating Income | 56.50% | 9.33% | |||
| Income Before Tax | 129.60% | -345.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 129.60% | -345.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 129.60% | -345.84% | |||
| EBIT | 56.50% | 9.33% | |||
| EBITDA | 56.90% | 8.40% | |||
| EPS Basic | 100.08% | -5,847.11% | |||
| Normalized Basic EPS | 100.28% | -7,598.94% | |||
| EPS Diluted | 99.98% | -5,847.11% | |||
| Normalized Diluted EPS | 100.06% | -7,598.94% | |||
| Average Basic Shares Outstanding | 10,525.58% | -94.21% | |||
| Average Diluted Shares Outstanding | 45,827.76% | -94.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||